Sign in
TerminatedPhase 2

Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT)

Key facts

Who runs it
David J. Gagnon
Where
Portland, United StatesSee the site
Trial code
Status
Terminated
Phase
Phase 2
People taking part
53 people enrolled
Started
20 Aug 2021
Ended
1 Nov 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Standard of care without prophylaxis
  • Antibiotic prophylaxis
Record updated
17 April 2025
Why it stopped
Lapse in funding

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • ≥18 years of age
  • Comatose (do not follow simple verbal commands)
  • Have any initial heart rhythm (shockable or non-shockable)
  • OHCA including the emergency department

Who cannot take part

  • Interval >6 hours from ICU admission to study drug receipt
  • Clinical bacterial infection prior to hospital admission defined as any one of the following:; Infectious prodrome preceding OHCA; Active course of antibiotics for infection prior to admission; Active infection documented in the electronic medical record; Family or surrogate endorsement of an active infection
  • In-hospital cardiac arrest
  • Preexisting terminal disease making 180-day survival unlikely
  • Name on opt-out list
  • Refused informed consent
  • Emergent coronary artery bypass grafting
  • Anaphylaxis or angioedema to beta-lactam antibiotics (i.e., cephalosporins or penicillins)
  • Under legal guardianship or prisoner
  • Known colonization with methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin-resistant enterococcus (VRE)

Where in United States

  • Maine Medical CenterPortland, United States

About the trial

What the trial wants to find out

Randomized-controlled trial and microbiome assessment to understand the risk-to-benefit ratio of prophylactic antibiotics (Ceftriaxone) vs placebo in patients with pneumonia and inflammation after cardiac arrest outside the hospital.

The 2 groups in the trial

  • No prophylaxis (placebo)Existing treatment, for comparison

    Standard care without antibiotic prophylaxis and treatment of infection if clinically warranted. Administer antibiotics in response to infection.

    Treatment: Standard of care without prophylaxis

  • ProphylaxisTreatment being tested

    Antibiotic prophylaxis for 3 days. Antibiotic prophylaxis with Ceftriaxone 2 gm IV q12h for 3 days.

    Treatment: Antibiotic prophylaxis

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Ceftriaxone to PRevent pneumOnia and inflammatTion aftEr Cardiac arresT (PROTECT): a Randomized-controlled Trial and Microbiome Assessment
Publications
Record updated
17 April 2025